These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 26683756)

  • 1. Predictors of weight-loss response with glucagon-like peptide-1 receptor agonist treatment among adolescents with severe obesity.
    Nathan BM; Rudser KD; Abuzzahab MJ; Fox CK; Coombes BJ; Bomberg EM; Kelly AS
    Clin Obes; 2016 Feb; 6(1):73-8. PubMed ID: 26683756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial.
    Kelly AS; Rudser KD; Nathan BM; Fox CK; Metzig AM; Coombes BJ; Fitch AK; Bomberg EM; Abuzzahab MJ
    JAMA Pediatr; 2013 Apr; 167(4):355-60. PubMed ID: 23380890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating appetite/satiety hormones and eating behaviours as predictors of weight loss maintenance with GLP-1RA therapy in adolescents with severe obesity.
    Bensignor MO; Kelly AS; Kunin-Batson A; Fox CK; Freese R; Clark J; Rudser KD; Bomberg EM; Ryder J; Gross AC
    Pediatr Obes; 2024 May; 19(5):e13105. PubMed ID: 38339799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experiences with Glucagon-Like Peptide-1 Receptor Agonist in Children with Acquired Hypothalamic Obesity.
    van Schaik J; Begijn DGA; van Iersel L; Vergeer Y; Hoving EW; Peeters B; van Santen HM
    Obes Facts; 2020; 13(4):361-370. PubMed ID: 32781455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men.
    Muskiet MH; Tonneijck L; Smits MM; Kramer MH; Diamant M; Joles JA; van Raalte DH
    Diabetes Obes Metab; 2016 Feb; 18(2):178-85. PubMed ID: 26636423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical effectiveness of exenatide in diabetic patients waiting for bariatric surgery.
    Iglesias P; Civantos S; Vega B; Pavón I; Guijarro G; Monereo S
    Obes Surg; 2015 Mar; 25(3):575-8. PubMed ID: 25589020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Off-label antiobesity treatment in patients without diabetes with GLP-1 agonists in clinical practice.
    Sauer N; Reining F; Schulze Zur Wiesch C; Burkhardt T; Aberle J
    Horm Metab Res; 2015 Jul; 47(8):560-4. PubMed ID: 25230325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany.
    Miller LA; Burudpakdee C; Zagar A; Bhosle M; Reaney M; Schabert VF; Bruhn D
    J Med Econ; 2012; 15(4):746-57. PubMed ID: 22443463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome.
    Sze L; Purtell L; Jenkins A; Loughnan G; Smith E; Herzog H; Sainsbury A; Steinbeck K; Campbell LV; Viardot A
    J Clin Endocrinol Metab; 2011 Aug; 96(8):E1314-9. PubMed ID: 21632815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg.
    Malmenäs M; Bouchard JR; Langer J
    Clin Ther; 2013 Jun; 35(6):795-807. PubMed ID: 23642290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes.
    Molina Vega M; Muñoz-Garach A; Tinahones FJ
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):207-217. PubMed ID: 29260924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study.
    Paul SK; Klein K; Maggs D; Best JH
    Cardiovasc Diabetol; 2015 Jan; 14():10. PubMed ID: 25616979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia.
    Ishøy PL; Fagerlund B; Broberg BV; Bak N; Knop FK; Glenthøj BY; Ebdrup BH
    Acta Psychiatr Scand; 2017 Jul; 136(1):52-62. PubMed ID: 28260235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New association of bone morphogenetic protein 4 concentrations with fat distribution in obesity and Exenatide intervention on it.
    Wang X; Chen J; Li L; Zhu CL; Gao J; Rampersad S; Bu L; Qu S
    Lipids Health Dis; 2017 Apr; 16(1):70. PubMed ID: 28376799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity.
    Burcelin R; Gourdy P
    Obes Rev; 2017 Jan; 18(1):86-98. PubMed ID: 27636208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity.
    Weghuber D; Forslund A; Ahlström H; Alderborn A; Bergström K; Brunner S; Cadamuro J; Ciba I; Dahlbom M; Heu V; Hofmann J; Kristinsson H; Kullberg J; Ladinger A; Lagler FB; Lidström M; Manell H; Meirik M; Mörwald K; Roomp K; Schneider R; Vilén H; Widhalm K; Zsoldos F; Bergsten P
    Pediatr Obes; 2020 Jul; 15(7):e12624. PubMed ID: 32062862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes.
    Blonde L; Pencek R; MacConell L
    Cardiovasc Diabetol; 2015 Feb; 14():12. PubMed ID: 25645567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials.
    Bettge K; Kahle M; Abd El Aziz MS; Meier JJ; Nauck MA
    Diabetes Obes Metab; 2017 Mar; 19(3):336-347. PubMed ID: 27860132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.